3-Methyladenine (3-MA)

目录号：S2767 别名： NSC 66389

3-Methyladenine (3-MA) Chemical Structure

Molecular Weight(MW): 149.15

3-Methyladenine (3-MA)是一种选择性PI3K抑制剂，作用于Vps34和PI3Kγ，在 HeLa细胞中IC50分别为25 μM和60 μM；永久性抑制I型PI3K，但对III型PI3K的抑制是短暂的，也会阻断自噬体的形成。

规格 价格 库存 购买数量  
RMB 579.66 现货
RMB 3010.37 现货
有超大折扣
大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834   |   Email：info@selleck.cn

客户购买Selleck的此次产品后发表的文献8篇：

客户使用该产品的5个实验数据：

  • MDC-labeled vacuoles were induced by AZD2014 and inhibited by autophagy inhibitor (3-MA). SMMC-7721 cells were treated with AZD2014 or rapamycin at concentrations of 100 and 600 nM, respectively, for 48 hours in the presence or absence of 3-MA, and then stained with MDC. Cells were immediately observed under a confocal microscope. Cells in the control group were treated with DMSO. bars, 20 μm.

    Am J Cancer Res, 2015, 5(1): 125-139. 3-Methyladenine (3-MA) purchased from Selleck.

    Cells were treated with DMSO, TDCIPP (100 μM) only, or pretreated with 3-MA before treatment with TDCIPP (100 μM). LC3 conversion and beclin-1 and p62 expression were assessed by western blotting at 24 h

    Food Chem Toxicol, 2017, 100:183-196. 3-Methyladenine (3-MA) purchased from Selleck.

  • PC-9/ER cells were treated with CX-4945 (5 mM) for 48 h in the presence or absence of 3-MA (2 mM) and Atg7 siRNA (100 nM). Cleavage of PARP-1 and caspase-3 was shown by Western blot analysis. CT: without CX-4945; CX: CX-4945; CX+G: CX-4945 + gefitinib; CX+E: CX-4945 + erlotinib.

    PLoS One, 2014, 9(12): e114000 . 3-Methyladenine (3-MA) purchased from Selleck.

    After getting treated with 10 μM compound C for indicated time periods with or without 50 μM 3-MA (C) pre-treatment for 1 h, the levels of indicated proteins in QBC939 and RBE cells were analyzed using Western blot.

    J Cell Biochem, 2017, 119(7):5538-5550. 3-Methyladenine (3-MA) purchased from Selleck.

  • A: The survival ratio of AML12 cells was measured after treatment with rapamycin or 3-MA; B: Western blot was used to detect the expression of LC3 and P62 in AML12 cells treated with Rapamycin or 3-MA.

    World J Gastroenterol, 2016, 22(18): 4501-4514.. 3-Methyladenine (3-MA) purchased from Selleck.

产品安全说明书

PI3K抑制剂选择性比较

生物活性

产品描述 3-Methyladenine (3-MA)是一种选择性PI3K抑制剂，作用于Vps34和PI3Kγ，在 HeLa细胞中IC50分别为25 μM和60 μM；永久性抑制I型PI3K，但对III型PI3K的抑制是短暂的，也会阻断自噬体的形成。
靶点
Vps34 [1]
(HeLa cells)		 PI3Kγ [1]
(HeLa cells)
25 μM 60 μM
体外研究

3-MA对Vps34轻微的偏向性可能是由于Vps34中某个特异性的疏水环形结构可以环绕在3-MA的3-甲基基团外面造成的[1] 。据报道对于正常培养和饥饿处理的癌细胞3-MA都能引起细胞死亡。3-MA还可以不通过抑制自吞噬来抑制细胞迁移和入侵，这表明3-MA 除了抑制自吞噬之外还有其它生物功能。3-MA可以造成半胱天冬酶依赖的细胞死亡，这一功能与它对自吞噬的抑制无关。用5mM 3-MA处理葡萄糖饥饿Hela细胞可降低gfp-lc3阳性细胞比例至23%。3-MA处理细胞12到48小时内 LC3-I 的水平上升而LC3-II 水平下降。LC3-I转为为 LC3-II 的过程被3-MA抑制了。 2.5 mM 或5 mM 3-MA 处理HeLa 细胞一天并不影响细胞存活率, 而 10 mM 3-MA 处理一天会造成细胞存活率下降25.0% 。 2.5, 5 或 10 mM 3-MA 处理细胞两天分别使细胞存活率下降 11.5%, 38.0% 和79.4% 。3-MA 降低细胞存活率的作用具有时间和剂量依赖特性。3-MA 明显缩短nocodazole诱导的前中期阻断时间[2]。3-MA 通过抑制自吞噬来抑制SU11274诱导的细胞死亡[3]。 在野生型MEF细胞中延长 3-MA处理时间 (最多 9 小时) 明显造成 LC3 I 到 II 转换。延长 3-MA处理时间会明显增加GFP-LC3的聚集而wortmannin不具有此功能。3-MA介导的LC3 转换和游离 GFP 释放是ATG7依赖的。 3-MA处理会导致 p62 蛋白水平明显升高。即使在Atg5−/− 的MEF细胞中3-MA 也会使p62 水平升高，就像在DOX介导的ATG5缺失的细胞中一样 。3-MA以不同方式抑制 I 型和 III型 PI3K。与野生型细胞相比，在Tsc2−/−细胞中3-MA诱导的 LC3 I 到 LC3 II 转换过程大幅下降。3-MA会破坏mTOR复合物1的拮抗自吞噬功能[4]。
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
95D MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYW2NYFpO22P MYGybC=> MlfGSG1UVw>? NYDzV4lOemWmdXPld{Boem:5dHigbY5pcWKrdH;yfUBm\m[nY4Sgc4YhSkSPQx?= M1e4cFI2PzF4NU[x
A549  MmLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXizcW0> MlS1Nog> MUXEUXNQ NHrLUVFz\WS3Y3XzJIdzd3e2aDDpcohq[mm2b4L5JIVn\mWldDDv[kBDTE2F NFfhe5UzPTdzNkW2NS=>
95D NFrTNFZCeG:ydH;zbZMhSXO|YYm= MmG3OY1O NVzGNW9TOmh? NX71Vm1sTE2VTx?= MWDpcohq[mm2czDCSG1ENWmwZIXj[YQh[XCxcITveIlkKGOnbHyg[IVifGh? MXKyOVcyPjV4MR?=
A549  MmfDRZBweHSxc3nzJGF{e2G7 NIL2clM2dU1? NFnVfHMzcA>? NY\rO29{TE2VTx?= MV\pcohq[mm2czDCSG1ENWmwZIXj[YQh[XCxcITveIlkKGOnbHyg[IVifGh? NGrGVmgzPTdzNkW2NS=>
NBL-W-S  M3vuS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TjZlFuVQ>? NHrRWGM3cA>? Ml7t[Y5p[W6lZYOgS2FPXC14MTD0c5hq[2m2eR?= M{DBNVI2OzJ|MkKy
NBL-W-S  MV\BdI9xfG:|aYOgRZN{[Xl? NUHqV5dJOW2P M4TsbVZp NGHh[WxqdmO{ZXHz[ZMh[2WubDDhdI9xfG:|aYOgbY5lfWOnZDDifUBISU6WLU[x Mn3uNlU{OjN{MkK=
A2780cp  NHHEe|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV[xcW0> NXvOcnh7OWh? MnfJbY5kemWjc3XzJINqe3CuYYTpck1qdmS3Y3XkJINmdGxiZHXheIg> NGXrOVkzPTN{Mk[5OC=>
A549  MlruSpVv[3Srb36gRZN{[Xl? MoHmOY1O MkG0Nog> NY\sRnBHe3WycILld5NmeyCVUFOgbY5lfWOnZDDhZ4N2dXWuYYTpc44hd2ZiTFOzMWlK NX7nRnJvOjV{OEW2Nlg>
H157 MWrGeY5kfGmxbjDBd5NigQ>? MofwOY1O MUmybC=> NIL0dmN{fXCycnXzd4V{KFOSQzDpcoR2[2WmIHHjZ5VufWyjdHnvckBw\iCOQ{OtTWk> Mn:1NlUzQDV4Mki=
MDR M2jIeGFxd3C2b4Ppd{BCe3OjeR?= MnLjNVBuVQ>? NWXldnRoPmh? M3;VUpN1emWwZ4To[Y5{KHSqZTDwc5dmeiCxZjDhcpRq[2GwY3XyJIRzfWe| NUi4fJI2OjVyMUm3NFE>
HT-29  MX3BdI9xfG:|aYOgRZN{[Xl? NEPjS4sydU1? NYTSZ4hQPDiq NG\FVWhFVVOR M4TqV4VvcGGwY3XzJIJwenSnen;tbYIucW6mdXPl[EBk\WyuII\pZYJqdGm2eTDsc5N{ MYiyOFg1OjF3OB?=
Microglia  NFLSRYVCeG:ydH;zbZMhSXO|YYm= MWG1cW0> M372[VI1cA>? M2eyUIRm[3KnYYPld{BpgXCxeHnhMYlv\HWlZXSgZ4VtdCCmZXH0bC=> NIi5SpEzPDhzOE[wNS=>
A2780cp MWXBdI9xfG:|aYOgRZN{[Xl? NWLuPFZGOi53bV2= Mk\DNYg> MlLR[IRJOk9? MX;lcohidmOnczDjbZNxdGG2aX6tbY5lfWOnZDDj[YxtKGSnYYTo MVuyOFgyPzl2Nh?=
HepG2 MUnGeY5kfGmxbjDBd5NigQ>? MnP3OY1O MUK0bC=> MoH5bY5kemWjc3XzJGhNKHKnbHXhd4U> MoH1NlQ4OTN3OEe=
A549 MonJRZBweHSxc3nzJGF{e2G7 MV[1cW0> NVr2Vmg{PDiq NIr5[Idl\WO{ZXHz[ZMhfGinIIDldoNmdnSjZ3Wgc4Yh[2WubDDk[YF1cCCjbnSg[ZhxemW|c3nvckBt\X[nbIOgc4Yh[2G|cHHz[U0{NCCEZXPsbY4uOSCjbnSgUGM{NUmL Mnj5NlQ4ODZ|MEO=
U2OS MlrvRZBweHSxc3nzJGF{e2G7 MmL4NVBuVQ>? MnjmNlRp NXv5cWY2cW62ZX7zbYZq\XNidHjlJIdzd3e2aDDpcohq[mm2aX;uJI9nKHSqZTDVNm9UKGOnbHzzJIlv\HWlZXSgZpkhTG:6 MUiyOFY{QTBzMx?=
Saos-2 MYPBdI9xfG:|aYOgRZN{[Xl? NYLuNXdWOTCvTR?= MXSyOIg> MVrpcpRmdnOrZnnld{B1cGViZ4Lve5RpKGmwaHnibZRqd25ib3[geIhmKFV{T2OgZ4VtdHNiaX7keYNm\CCkeTDEc5g> MoX0NlQ3OzlyMUO=
A549 MYLBdI9xfG:|aYOgRZN{[Xl? NFr3[XoyOG2P M2noVFQ5cA>? MnrlZYNk\WyncnH0[ZMhfGinIILl[JVkfGmxbjDv[kBk\WyuII\pZYJqdGm2eTDpcoR2[2WmIHL5JHBVYA>? Ml[1NlQ3OjZ5MkK=
HCT116  MXnBdI9xfG:|aYOgRZN{[Xl? MYG1cW0> MlH0NlRp MXnlcohidmOnczD0bIUh[XCxcITvd4l{KGmwZIXj[YQh[nliYYDp[4VvcW5? M2KxTFI1PjJ4NUKy
HGC-27 MXTGeY5kfGmxbjDBd5NigQ>? M3HlZlExdU1? M1XvS|Fp M{fuXYlvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0fUBtd3O|IHL5JHJCTDByMTDvdkBOUy1{MkC2 MmHONlQ1OTZ|NEm=
U2OS  NU\mdFBSTnWwY4Tpc44hSXO|YYm= MojwNE42NzGvTR?= MkTtOFhp M1TTOYlv\HWlZYOgd4FtcW6xbYnjbY4ucW6mdXPl[EBk\WyuII\pZYJqdGm2eTDsc5N{ MnTiNlQ{PTh|NEK=
MG-63 MVjGeY5kfGmxbjDBd5NigQ>? MX6wMlUwOW2P MVe0PIg> M{LWc4lv\HWlZYOgd4FtcW6xbYnjbY4ucW6mdXPl[EBk\WyuII\pZYJqdGm2eTDsc5N{ MVOyOFM2QDN2Mh?=
MG-63 M{XPXmFxd3C2b4Ppd{BCe3OjeR?= MV2wMlUwOW2P MnvFN|Jp MUTlcohidmOnczDzZYxqdm:veXPpck1qdmS3Y3XkJINmdGxiYYDvdJRwe2m| NX;zSm5LOjR|NUizOFI>
MG-63 MnHXRZBweHSxc3nzJGF{e2G7 NYTTU3JjOTCvTR?= MVGxNog> MUjlcohidmOnczDEVE1qdmS3Y3XkJIFxd3C2b4Ppdy=> NVnocnFzOjR|NUizNFE>
NTUB1 MmfmRZBweHSxc3nzJGF{e2G7 MkPPOY1O NHLTcFcyNjWq MkL3dI91\W62aXH0[ZMh[2WuZXPvfIljNWmwZIXj[YQh[XCxcITvd4l{ NGGxNoIzPDN2OUG3Oi=>
T24 Mlv4RZBweHSxc3nzJGF{e2G7 M2LmXFVuVQ>? NIf4RpUyNjWq M4n5TJBwfGWwdHnheIV{KGOnbHXjc5hq[i2rbnT1Z4VlKGGyb4D0c5Nqew>? Mn;iNlQ{PDlzN{[=
SGC-7901  NULTSWFISXCxcITvd4l{KEG|c3H5 NILaWHkzdU1? MX6xbC=> MoXMbY5kemWjc3XzJGNCNTRiaX7keYNm\CCjcH;weI9{cXN? NVfSOYFKOjR|MkGzOFA>
SMMC-7721 MWrBdI9xfG:|aYOgRZN{[Xl? NHXsdpUzdU1? MXGxbC=> NH7tO|hqdmO{ZXHz[ZMhS0FvNDDpcoR2[2WmIHHwc5B1d3Orcx?= M2\tUFI1OzJzM{Sw
ECSCs  MVrBdI9xfG:|aYOgRZN{[Xl? MlfsNVBuVQ>? M1ew[lRp MUPk[YNz\WG|ZYOgdoFx[W27Y3nuMZRz\WG2ZXSgZZBweHSxc3nz NYq3[Vl5OjR|MUmxNFk>
MCF-7  M1P3dWZ2dmO2aX;uJGF{e2G7 NX7HTXNXOTCvTR?= NE[yUXEzPGh? NImyVZhqdmirYnn0d{B1cGViYYX0c5Bp[We7IHnu[JVk\WRiYomgZ4hmdW:2aHXyZZB6KGS{dXfz M2D4Z|I1OzF3NUe4
UOK257 M3vWS2Fxd3C2b4Ppd{BCe3OjeR?= MX21cW0> NXjqXoEzO2h? NX[xS5ZR\W6qYX7j[ZMheGGlbHn0ZZhmdC2vZXTpZZRm\CCjcH;weI9{cXQEoB?= NVu1Olk6OjR|MEW2NFQ>
ACHN-5968 NIPobmpCeG:ydH;zbZMhSXO|YYm= M{nqZVVuVQ>? NF\5ZYE{cA>? NXHqRYpl\W6qYX7j[ZMheGGlbHn0ZZhmdC2vZXTpZZRm\CCjcH;weI9{cXQEoB?= NH7wNHMzPDNyNU[wOC=>
Huh7 NXnSUIc6SXCxcITvd4l{KEG|c3H5 MkPsNo1O NXXKXFBKOTKq Mo\WSG1UVw>? NUDhfFdEcW6qaXLpeJMhSVqGOEC1OU1qdmS3Y3XkJINmdGxiZHXheIg> MnvBNlQzQTd|MEC=
Hep3B Ml;ZRZBweHSxc3nzJGF{e2G7 MWSycW0> Mn62NVJp M17aZ2ROW09? MnHobY5pcWKrdIOgRXpFQDB3NT3pcoR2[2WmIHPlcIwh\GWjdHi= Mnr1NlQzQTd|MEC=
RKO M1T1fWZ2dmO2aX;uJGF{e2G7 MVqycW0> NGrn[3IycA>? NE\TfGhFVVOR NH;U[4JmdmijbnPld{Bk\WyuIHTlZZRpKGK7IHflcIRidmGveXPpci=> M1nkcVI1OjlzN{e3
HepG2 E47 M3HqZWZ2dmO2aX;uJGF{e2G7 NYjue4k2Oi53bV2= M1noZ|Q5cA>? M3rTWYlv[3KnYYPld{B1cGVidH;4bYNqfHlib3[gRWEtKEKVTzygZY5lKEOFbES= NXzIR4Q1OjR{N{O3N|g>
LoVo  NUWyfYFXSXCxcITvd4l{KEG|c3H5 MV21cW0> MUO0PIg> MXflcohidmOnczDER2EucW6mdXPl[EBieG:ydH;zbZMv NF3NU|EzPDJyMUixNi=>
WiDr MmPWSpVv[3Srb36gRZN{[Xl? NUHle2RuOTCvTR?= NVTXc|VVOWh? MkP1bY5pcWKrdIOgVGNDVC2rbnT1Z4VlKEyFMzDJTUBmgHC{ZYPzbY9v MkjYNlQyQTB2OEm=
H1299  NF71O2lHfW6ldHnvckBCe3OjeR?= Mmq0NVBuVQ>? MUO0bC=> NWrYRmdGcW6lcnXhd4V{KGOrc4DsZZRqdi2rbnT1Z4VlKGOnbHyg[IVifGh? NYC1VoNDOjRzN{OyNFg>
H460 MYfGeY5kfGmxbjDBd5NigQ>? MV2xNI1O MYe0bC=> MoWwbY5kemWjc3XzJINqe3CuYYTpck1qdmS3Y3XkJINmdGxiZHXheIg> NXfJbFlZOjRzN{OyNFg>
A549 NYjWc2hSTnWwY4Tpc44hSXO|YYm= MkLaNVBuVQ>? Mn\NOIg> NYH6e|RWcW6qaXLpeJMh[XW2b4DoZYd6KGmwZIXj[YQh[nliaYLyZYRq[XSrb36= M1nPNFI1OTR{N{O1
Hep3B MXnBdI9xfG:|aYOgRZN{[Xl? MmfYOY1O NWXDeYdrOjSq MVnheJRmdnWjdHXzJHRPTi4QsTDwdo91\WO2aX;uJIFo[Wmwc4Sgd4VzfW1ic4ThdpZifGmxbj3t[YRq[XSnZDDhdI9xfG:|aYO= MnH6NlQxPjZ4OUO=
SMMC-7721 M1PxUWFxd3C2b4Ppd{BCe3OjeR?= MXi1cW0> NV:1e|RnOjSq NWrYOo9G[XS2ZX71ZZRmeyCWTl[t{tEheHKxdHXjeIlwdiCjZ3HpcpN1KHOncoXtJJN1[XK4YYTpc44udWWmaXH0[YQh[XCxcITvd4l{ MlrDNlQxPjZ4OUO=
HO8910 NWHQdJBTSXCxcITvd4l{KEG|c3H5 M4XUcVExdU1? NV7u[oNGOTKq Mnuz[Y5p[W6lZYOgRlE6NWmwZIXj[YQh[XCxcITvd4k> MYqyN|k5OzZzMB?=
MCF7 M4ryWGZ2dmO2aX;uJGF{e2G7 M1mzdlVuVQ>? M4S4W|I1cA>? NWWyb3FpcW6lcnXhd4V{KEO3TzDpcoR2[2WmIHPlcIwh\GWjdHi= NVmwRmxwOjN7NkK2Nlk>
HONE-1  MXHGeY5kfGmxbjDBd5NigQ>? Mm[2OY1O M3jhNlFp MVLy[ZBz\XO|ZYOgOpIudWWmaXH0[YQhWk:VIIDyc4R2[3Srb36= M2HBOlI{QDl{M{W4
HeLa MVrGeY5kfGmxbjDBd5NigQ>? NGLPZm0yOG2P M3\6UlJp MoLmd5VxeHKnc4Pld{BNSzNiSVmg[ZhxemW|c3nzc44> MmC5NlM5PjR5M{i=
HepG2 NWfYUZRCTnWwY4Tpc44hSXO|YYm= M170clExdU1? MUKyOIg> MnyxbY5pcWKrdIOgd4lVUUeDUj2gZY5lKEiEU2OtbY5lfWOnZDDheZRweGijZ4m= MUGyN|gyPzB2MB?=
SH-SY5Y NHvSc2VHfW6ldHnvckBCe3OjeR?= M2jvWFFuVQ>? NHjyfJIzPGh? MWDpcohq[mm2czD0bIUh[XW2b4DoZYd6KGmwZIXj[YQh[nliVF;DVC=> NXLM[2dOOjN5NEOxOFg>
SH-SY5Y MYPBdI9xfG:|aYOgRZN{[Xl? NVr5U3ZuPW2P MorrNYg> MX;hZo9tcXOqZYOgZ4Vt[XO2cn;sJI5mfXKxcILveIVkfGm4ZTDl[oZm[3R? NED3VoszOzZzOUO5OS=>
PC12  MYPGeY5kfGmxbjDBd5NigQ>? NWnmZmVQOTCvTR?= NV7CSHBoOjSq MXT3ZZRmeg>? Mn7WxsBqdmirYnn0d{BkcHmvb4TyfZB{cW5vbHnr[UBxem:2ZXHzc41idCCjY4Tpeol1gS5? NVnZe2ptOjN4MEO5O|k>
OV2008 NXnsNlVVSXCxcITvd4l{KEG|c3H5 MoS3OY1O MYKyOIg> M3\LSoNwdn[ncoTzJGZVYTd{MDD3bZRpKEOGRGCgbY51dyCjbjDh[IRqfGm4ZTDl[oZm[3RidH;3ZZJleyCtaXzsbY5oKG:4YYLpZY4h[2GwY3XyJINmdGy| MoHwNlM2QTJ{OEG=
A2780 NHTm[2FCeG:ydH;zbZMhSXO|YYm= M4nwb|VuVQ>? NF3LN28zPGh? MYrjc453\XK2czDGWHk4OjBid3n0bEBETESSIHnueI8h[W5iYXTkbZRqfmViZX\m[YN1KHSxd3Hy[JMhc2mubHnu[{BwfmG{aXHuJINidmOncjDj[Yxtew>? NIDaXYgzOzV7MkK4NS=>
Saos-2  M{TD[WFxd3C2b4Ppd{BCe3OjeR?= M3fj[lFuVQ>? M3P1NFk3cA>? NF3HUFFqdmO{ZXHz[ZMh[2WubDDk[YF1cCCrbnT1Z4VlKGK7IGDDXC=> NGe4OI8zOzV4M{G3NS=>
1321N1 NGnyN5BEgXSxdH;4bYNqfHliQYPzZZk> NVzNfZNYPW2P MXKyOIg> NHHCWlRxem:2ZXP0d{Bk\WyuIHHnZYlve3RiUFPOMYlv\HWlZXSgeI95cWOrdIm= MYmyN|UzPTJ4NR?=
SH-SY5Y NFPEZ4FEgXSxdH;4bYNqfHliQYPzZZk> M2jQdFVuVQ>? MnrhNlRp NIrCW5JqdmO{ZXHz[ZMhWEOQIITvfIlkcXS7 MoXQNlM2OjV{NkW=
HT-29  M3vQZ2Z2dmO2aX;uJGF{e2G7 NXK4dopnOW2P NFnz[2o1QC97Nni= MmHHbY5pcWKrdIOgRW1RUyCrbnT1Z4V{KGG3dH;wbIFocWNiY3XscEBl\WG2aB?= MnnRNlM2ODh{N{K=
OR6 NInwZ|dHfW6ldHnvckBCe3OjeR?= NWq4UXN2OTCvTR?= MV:3Nog> NYW0eW5Ye3WycILld5NmeyCKQ2[gdoVxdGmlYYTpc44h[W6mIH\vdo1ifGmxbjDv[kBifXSxcHjh[49{d22ncx?= M2PHN|I{Ozl3OEe1
Hela  MlzKSpVv[3Srb36gRZN{[Xl? M1jtRlVuVQ>? MkTiNlRp NHvoS4xqdmirYnn0d{B{fGG{dnH0bY9vNWmwZIXj[YQh[XW2b4DoZYd6 MmriNlM{QTV4N{m=
MCF-7  M1;5T2Z2dmO2aX;uJGF{e2G7 MWG1cW0> MV:yOIg> M131V4lvcGmkaYTzJJN1[XK4YYTpc44ucW6mdXPl[EBifXSxcHjh[5k> M2jXRlI{Ozl3Nke5
HUVECs MWPGeY5kfGmxbjDBd5NigQ>? MmfQN41O MYOyOIg> NYfFcoI1[myxY3vzJJRp\SCycn;0[YN1cX[nIHXm[oVkfCCxZjDy[ZN3\XKjdILvcEBjgSCrbnjpZol1cW6pIHH1eI9xcGGpeR?= NW\Ve5hLOjN|NUi5Nlg>
T24 NEDqUY5HfW6ldHnvckBCe3OjeR?= NG\yd4wyOG2P NE\Qd2oycA>? MXXy[YR2[2W|IITo[UBkdGWjdnHn[UBw\iCOQ{OgZYZ1\XJiYnHpZ4FtcW5idILlZZRu\W62 MnTqNlM{PTRyOEC=
U251MG  NX\T[2J4TnWwY4Tpc44hSXO|YYm= M4LLT|NuVQ>? M33RVlFp Mlnpd5VxeHKnc4Pld{BNSzNvSVmgdJJwfGWrbjDlfJBz\XO|aX;u Ml7aNlM{Ozh4MUi=
GTL-16  NI\p[5NCeG:ydH;zbZMhSXO|YYm= MYS1cW0> M37jZ|I1cA>? MVfy[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGG|IHPvcZBiemWmIITvJINmdGy|IITy[YF1\WRid3n0bEBOTVRiaX7obYJqfG:{cx?= MUWyN|MyOzR7MB?=
T-47D NEHhS3FHfW6ldHnvckBCe3OjeR?= NFz6TJAyOG2P M4OyflJp NVThbXNrcW6qaXLpeJMh[XW2b4DoZYd6KHC{b3Pld5Mh[W6mIHnuZ5Jm[XOnczDyZZBidXmlaX6gbY5lfWOnZDDhdI9xfG:|aYO= M3n5TFI{OzByMEK2
PaCa44 M3Pnb2Fxd3C2b4Ppd{BCe3OjeR?= MYWyMlVuVQ>? MnvWNYg> MmfFdoVlfWOnc9Mg[4VvcXCrbj3t[YRq[XSnZDDhdI9xfG:|aYO= NEHJSmYzOzF{NEGxNi=>
MDA-MB231 MXHGeY5kfGmxbjDBd5NigQ>? M33zWFVuVQ>? M4XYb|Fp M2nFZ4lv[3KnYYPld{Bz\XO4ZYLheJJwdC2vZXTpZZRm\CClYYPwZZNmKGGldHn2ZZRqd25iYX7kJINmdGxiZHXheIg> MX[yN|A5QDh3MB?=
HeLa NVvRV3dwSXCxcITvd4l{KEG|c3H5 MnW0NVBuVQ>? NWDk[Y5pOmh? NHjZXmll\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgZ48ufHKnYYTt[Y51KHerdHigVGVK NI\XT3QzOzByMEGzOS=>
SK-HEP-1 NV7UToN2SXCxcITvd4l{KEG|c3H5 M{XGNVExdU1? M1LKOFFp MkjQdJJwfGWldIOgZYdicW6|dDDheZRweGijZ4mgZY5lKGmwZIXj[ZMh[XCxcITvd4l{KGmwIHL1[oFtcW5vdILlZZRm\CClZXzsdy=> NHvqO2UzOjh3OE[0PS=>
HepG2 Mo\jRZBweHSxc3nzJGF{e2G7 MoLQN41O M4f3c|Vp NYj3fGFQemWmdXPld{Bk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JHFFew>? M37VXFIzQDN4NUm1
MCF-7  MVnGeY5kfGmxbjDBd5NigQ>? NFntOWIzdU1? NFLzZWwzPGh? NYjRVIJmcW6qaXLpeJMh[XW2b4DoZYd6KGmwZIXj[YQh[nliVF5CpC=> NH;R[mQzPDl5ME[3Oi=>
MDA-MB-231 M4DDV2Z2dmO2aX;uJGF{e2G7 NWSyeYNkOm2P M3T4XlI1cA>? MXHpcohq[mm2czDheZRweGijZ4mgbY5lfWOnZDDifUBVVcLi MVWyOFk4ODZ5Nh?=
MCF-7  MmLGSpVv[3Srb36gRZN{[Xl? NXvYXYVLOm2P NGXRdos1QGh? Mkf5dJJwdW:2ZYOgWG0ucW6mdXPl[EBk\WyuIHTlZZRp MkfmNlQ6PzB4N{[=
MDA-MB-231 MXjGeY5kfGmxbjDBd5NigQ>? Mk\nNo1O NIfmcYU1QGh? NWnEcVJPeHKxbX;0[ZMhXE1vaX7keYNm\CClZXzsJIRm[XSq MnfaNlQ6PzB4N{[=
PANC-1  MWfBdI9xfG:|aYOgRZN{[Xl? NIfUO4MydU1? NEnoWZc1QGh? M1fqdmROW09? NXLQVmJF\W6qYX7j[ZMh[m:{dHX6c41q[i2rbnT1Z4VlKGOnbHygeoli[mmuaYT5JIxwe3N? Mk\4NlQ5PDJzNUi=
MDA-MB 231 MnmyRZBweHSxc3nzJGF{e2G7 NV3lbpluPW2P NFjZ[pExNjWq MYftc4R2dGG2ZYOgWI9kd22rbtMuxsBqdmS3Y3XkJIFxd3C2b4Ppdy=> MWmyOFg{ODd6MR?=
Microglia  M4\2SWFxd3C2b4Ppd{BCe3OjeR?= MlSwOY1O M1\SRVI1cA>? M4riZ4Rm[3KnYYPld{BpgXCxeHnhMYlv\HWlZXSgZ4VtdCCmZXH0bC=> NYLwRYdxOjR6MUi2NFE>
A2780cp NFrYWJNCeG:ydH;zbZMhSXO|YYm= NXy5eoR3Oi53bV2= MXWxbC=> MUnk[GgzVw>? M32wbIVvcGGwY3XzJINqe3CuYYTpck1qdmS3Y3XkJINmdGxiZHXheIg> NVfW[GxXOjR6MUe5OFY>
HepG2 MXXGeY5kfGmxbjDBd5NigQ>? M3;sXlVuVQ>? NHvqN2Y1cA>? MoHnbY5kemWjc3XzJINmdGy3bHHyJIxmfmWuczDv[kBJVMLi NYfZS4dHOjR5MUO1PFc>
U2OS MmDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPKN|dFOTCvTR?= M1rOXFI1cA>? MXTpcpRmdnOrZnnld{B1cGViZ4Lve5RpKGmwaHnibZRqd25iaX7keYNm\CCkeTDEc5g> M3XXTFI1PjN7MEGz
HCT116 MW\BdI9xfG:|aYOgRZN{[Xl? M3e4TFVuVQ>? M2SxZ|I1cA>? M{HFTWROW09? MUPlcohidmOnczDhdIlo\W6rbj3pcoR2[2WmIHPlcIwh\GWjdHi= MnvVNlQ3OjZ3MkK=
MCF-7  MoDtRZBweHSxc3nzJGF{e2G7 NGXPT2UxNjGvTR?= MWG2bC=> NYfYN3o{\W6qYX7j[ZMhe2m{dHnuc4wucW6mdXPl[EBieG:ydH;zbZM> MXOyNlc2OTl6OR?=
PC-3  MY\BdI9xfG:|aYOgRZN{[Xl? MUKycW0> MYKybC=> NU\TRphycW6lcnXhd4V{KE:UST3pcoR2[2WmIHPlcIwh\GWjdHi= MlriNlI4PDV3OEC=
U251  MYDBdI9xfG:|aYOgRZN{[Xl? Mnr4OY1O NUHpSXZCOjSq NUPXR2VRcW6lcnXhd4V{KFNzLXnu[JVk\WRiY3XscEBl\WG2aB?= M4Dyb|IzPTd7N{i4
HeLa  NHPsRlJCeG:ydH;zbZMhSXO|YYm= MnfxOY1O NX7TTVFJOjSq MU\pcoR2[2W|IHPhd5Bie2VvZHXw[Y5l\W62IHPlcIwh\GWjdHi= NH:zcnIzOjV2NUGyPC=>
A549 MUfGeY5kfGmxbjDBd5NigQ>? MnizNE4ydU1? Mn;NNlRp MkK5d5VxeHKnc4Pld{BUXTFzMke0MYlv\HWlZXSgZ4VtdCCmZXH0bC=> M{DhNFIzPDZ4OU[w
pDCs M2PmT2Z2dmO2aX;uJGF{e2G7 NITnRo4yOG2P NFrZWVQxNjWq NEHTW3fDqHKnZIXj[ZMhfGinIHnu[JVkfGmxbjDv[kBKTk5vzsGgZpkhe3OUTlG0NC=> NHPDVJczOjN7NkW5PS=>
BGC-823 NH3Q[pNHfW6ldHnvckBCe3OjeR?= M4XBXVVuVQ>? MV2ybC=> M1myWYlvcGmkaYTzJJRp\SC{YYTlJI9nKGG3dH;wbIFocWNiY3XscJM> MoW2NlI{OjJzNUK=
U937 MkfHSpVv[3Srb36gRZN{[Xl? M3XsV|JuVQ>? M1i5T|EzcA>? MnfQ[IVkemWjc3XzJJRp\SCjdYTvdIhi\3licnH0bY/DqA>? MVyyNlE2PTF3MB?=
Marc-145 MlzUSpVv[3Srb36gRZN{[Xl? NWjw[pBmPW2P MWmxNk8zPC9|Nni= M1PaUpJm\HWlZYOgeIhmKFCUUmPWJJRqfGW{czDhcoQhfGinIIDyc5RmcW5iZYjwdoV{e2mxbh?= NFvXdo4zOjFzOUmwNC=>
HBx  MW\BdI9xfG:|aYOgRZN{[Xl? M3vZW|ExdU1? NUPC[WwxPDiq MXfEUXNQ NI\1T|VqdmO{ZXHz[ZMh[2WubDDk[YF1cA>? M3\JOlIzODJyMEe4
MCF-7 MX3GeY5kfGmxbjDBd5NigQ>? M17aSFExdU1? MYK0PIg> MWjicI9kc3NiYYX0c5Bp[We7IHnu[JVk\WRiYomgZo9zfGW8b33pZi=> Mo\3NlE6OzF7M{e=
RMPI8226  NF7mWlRHfW6ldHnvckBCe3OjeR?= Ml7VOY1O MW[xbC=> NVrDbodYe3WycILld5NmeyC2aHWgcIV3\Wxib3[gZZV1d3CqYXf5JJVv\GW{IH71eJJq\W62IHTldIxmfGmxbh?= M{D0VlIyQTF3NkKw
PC12/TetOn MoLDSpVv[3Srb36gRZN{[Xl? MV2wMlEwOW2P NH7rfHQyQGh? NUKwOVJ2dGWjZIOgeI8h|rFvc4nuLHdVMSCjY3P1cZVt[XSrb36sJJRwgGmlaYT5MEBidmRib3zp[49u\XJiZn;ycYF1cW:wwrC= MnXTNlE6ODZ4NUm=
HeLa  NHrlb3lEgXSxdH;4bYNqfHliQYPzZZk> NELSc2kzdU1? MXOyOIg> MYnpcohq[mm2ZYOgeIhmKGO7dH;0c5hq[2m2eTDv[kB{cWyrYnnubY4hfG9iSHXMZUBk\Wyucz6= MmTuNlE5PzV|OEW=
Jurkat NVG2[IdlTnWwY4Tpc44hSXO|YYm= NGfiVWcyOG2P NIi0dm8ycA>? MmDP[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJGxEOy2LSTDhcoQhfGinIH\vdo1ifGmxbjDv[kBifXSxcHjh[49{d22ncx?= NF\obJozOTh4NECzOy=>
K562 M1W0WWZ2dmO2aX;uJGF{e2G7 NHvrOoYyOG2P NGPqU2sycA>? Mke3[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJGxEOy2LSTDhcoQhfGinIH\vdo1ifGmxbjDv[kBifXSxcHjh[49{d22ncx?= M2TP[VIyQDZ2MEO3
Nara-H NFez[YNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1GzblVuVQ>? M1:0UVQ5cA>? NVruPWVS\W6qYX7j[ZMhfGWvc3nyc4xqdXW|bXXkbYF1\WRic4XwdJJme3Orb36gc4YhVmG{YT3IJINmdGxicILvcIln\XKjdHnvci=> NV\NeYNXOjF6MEWwN|M>
HUVECs MkDhSpVv[3Srb36gRZN{[Xl? NVjhTnhoOTCvTR?= NGHmXnExNjWq MVTk[YNz\WG|ZYOgeIhmKEGJRT3CV2FqdmS3Y3XkJIF2fG:yaHHnfUBt\X[n M3nWTFIyPDZ6NUmy
HepG2 MknvRZBweHSxc3nzJGF{e2G7 MlvyNo1O NEHVVHcycA>? MVLlcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDj[YxtKGSnYYTo MYKyNVQ2OzZ7MR?=

... Click to View More Cell Line Experimental Data
体内研究 3-Methyladenine (3-MA)可以通过对磷酸肌醇3磷酸激酶(PI3K) 的作用来阻断自吞噬, 而PI3K的活性对于自噬体形成早期膜池的成核和组装是必须的。与SAH 处理组相比3-MA并不会改变出血的程度。与SAH +对照成分组相比经过3-MA预处理后会明显加重神经病学症状。3-MA处理会减少自吞噬发生[5]。 相反地,在SAH + 3-MA组里 断裂的半胱天冬酶表达量明显上调，与此一致的是与SAH + 对照成分组相比，SAH + 3-MA组中右脑皮层里原位末端标记阳性细胞数量明显增多[5]。

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验：[4]
+ 展开

Protein degradation assay:

HeLa cells are radiolabeled for 24 hours with 0.05 mCi/mL l-[U- 14C]valine. At the end of the labeling period, cells are rinsed three times with PBS. Cells are incubated for the designated times in either full medium or EBSS with or without the presence of 10 mM 3-Methyladenine.
细胞实验：[2]
+ 展开
  • Cell lines: HeLa 细胞系
  • Concentrations: 1-10 mM
  • Incubation Time: 3 分钟
  • Method: 用台盼蓝染色法分析细胞存活率（如HeLa细胞）。简言之, 经过3-MA处理后将贴壁的与漂浮的细胞都用PBS( pH 7.4)重悬，密度控制在每毫升1-2×106。加入等体积的0.4% 台盼蓝并彻底混匀。室温孵育3分钟后用血细胞计数器对细胞计数分析。
    (Only for Reference)
动物实验：[5]
+ 展开
  • Animal Models: 体重 300-350 g 的成年雄性Sprague–Dawley 大鼠
  • Formulation: 生理盐水配制
  • Dosages: 400 nM
  • Administration: 脑室给药
    (Only for Reference)

溶解度 (25°C)

体外 Water 10 mg/mL warmed (67.04 mM)
Ethanol 4 mg/mL (26.81 mM)
DMSO 3 mg/mL warmed (20.11 mM)

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 149.15
化学式

C6H7N5
CAS号 5142-23-4
稳定性 powder
别名 NSC 66389

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量：

总分子量：g/mol

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1：

    I'm also wondering whether it can be dissolved in water,or maybe something like culture medium,normal saline solution to form 10mM solution

  • 回答：

    As the reference (http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal. pone.0035665), 3-MA, which was found to inhibit autophagy at concentrations ranging from 1 to 10 mM was directly dissolved into the culture medium at the indicated concentrations. And we tested the solubility of S2767, and found the solubility of 3-MA in DMEM is 31 mg/mL at about 40°C.

Selleck产品目录册

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

相关PI3K产品

  • Taselisib (GDC 0032) New

    Taselisib (GDC 0032)是一种有效，下一代的β亚型PI3K抑制剂，作用于PI3Kα/δ/γ， IC50分别为0.29 nM/0.12 nM/0.97nM，比作用于PI3Kβ选择性高10倍以上。

  • Pilaralisib (XL147) New

    Pilaralisib (XL147)是一种选择性的可逆I型PI3K抑制剂，作用于PI3Kα/δ/γ，在无细胞试验中IC50为 39 nM/36 nM/23 nM，对PI3Kβ作用较低。Phase 1/2。

  • GNE-317 New

    GNE-317 是一种有效的，大脑渗透性 PI3K 抑制剂。

  • LY294002

    LY294002 是首个合成的已知抑制PI3Kα/δ/β的小分子，在无细胞测定中IC50分别为 0.5 μM/0.57 μM/0.97 μM；在溶液中比在Wortmannin中稳定，也能够阻断自噬体的形成。它不仅能够结合class I PI3Ks和其他PI3K相关的激酶，还能够结合一些与PI3K家族无关的新型靶点。

    Features:LY294002是选择性的, 可渗透细胞的特定PI3K抑制剂，可作用于酶的ATP结合位点，且抑制自体吞噬的螯合作用。

  • Idelalisib (CAL-101, GS-1101)

    Idelalisib (CAL-101, GS-1101) 是选择性p110δ抑制剂，在无细胞试验中IC50为 2.5 nM；对 p110δ 表现出的选择性是对 p110α/β/γ 的 40 到 300 倍，对p110δ的选择性是对 C2β，hVPS34，DNA-PK 和 mTOR的400到4000倍。

    Features:Calistoga 暗示 CAL-101治疗血液恶性肿瘤可能有更广泛的应用价值。

  • Wortmannin

    Wortmannin是一种首次命名的PI3K抑制剂，在无细胞试验中IC50为3 nM，对 PI3K 家族的选择性较低。也会抑制自噬体的形成，并有效抑制DNA-PK/ATM，在无细胞试验中IC50为16 nM和150 nM。

  • Dactolisib (BEZ235, NVP-BEZ235)

    Dactolisib (BEZ235, NVP-BEZ235) 是一种双重ATP竞争性 PI3K 和 mTOR 抑制剂，在无细胞试验中，抑制 p110α/γ/δ/β 和 mTOR(p70S6K) 的 IC50 分别为 4 nM /5 nM /7 nM /75 nM /6 nM。 在 3T3TopBP1-ER 细胞中抑制 ATR，IC50 为 21 nM，而对 Akt 和 PDK1 的抑制作用很弱。Phase 2。

  • Buparlisib (BKM120, NVP-BKM120)

    Buparlisib (BKM120, NVP-BKM120) 是一种选择性 PI3K 抑制剂，在无细胞试验中作用于p110α/β/δ/γ的IC50分别为 52 nM/166 nM/116 nM/262 nM。对 VPS34，mTOR，DNAPK 的作用效果下降，而对 PI4Kβ几乎没有活性。Phase 2。

    Features:BKM120是可用于口服的生物有效的PI3K抑制剂。

  • Pictilisib (GDC-0941)

    Pictilisib (GDC-0941) 是一种有效的PI3Kα/δ抑制剂，在无细胞试验中IC50为 3 nM，对p110β (11倍)和p110γ (25倍)具有适度的选择性。Phase 2。

  • Alpelisib (BYL719)

    Alpelisib (BYL719) 是一种有效的选择性PI3Kα抑制剂，在无细胞试验中IC50为 5 nM，对PI3Kβ/γ/δ具有极弱的作用。Phase 2。

Tags: 购买3-Methyladenine (3-MA) | 3-Methyladenine (3-MA)供应商 | 采购3-Methyladenine (3-MA) | 3-Methyladenine (3-MA)价格 | 3-Methyladenine (3-MA)生产 | 订购3-Methyladenine (3-MA) | 3-Methyladenine (3-MA)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID